Online Only Articles

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

University of Texas MD Anderson Cancer Center, Houston, TX, USA
Weill Cornell Medical Center, New York, NY, USA
Indiana University Simon Cancer Center, Indianapolis, IN, USA
Moffitt Cancer Center, Tampa, FL, USA
West Virginia University, Morgantown, WV, USA
Institut Paoli-Calmettes and Aix-Marseille University, Marseille, France
Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
David Geffen School of Medicine at University of California, Los Angeles, CA, USA
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux, France
University Hospital Schleswig-Holstein, Kiel, Germany
Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse III, Centre Hospitalier Universitaire de Toulouse, France
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
University of Texas MD Anderson Cancer Center, Houston, TX, USA
IRCCS AOU San Martino-IST, Genova, Italy
Kaposi Mor Teaching Hospital, Kaposvar, Hungary
Universitätsklinikum Münster, Germany
Sunesis Pharmaceuticals, Inc., South San Francisco, CA, USA
Sunesis Pharmaceuticals, Inc., South San Francisco, CA, USA
Sunesis Pharmaceuticals, Inc., South San Francisco, CA, USA
Sunesis Pharmaceuticals, Inc., South San Francisco, CA, USA
Sunesis Pharmaceuticals, Inc., South San Francisco, CA, USA
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Medical University of South Carolina, Charleston, SC, USA
Vol. 103 No. 11 (2018): November, 2018 https://doi.org/10.3324/haematol.2018.191361